FMS-like tyrosine kinase 3 (FLT3) mutations represent some of the most pivotal genetic alterations in acute myeloid leukemia (AML), influencing ...

AbbVie's Emrelis is the first non-small cell lung cancer therapy approved for patients with high c-Met expression levels who ...

InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the first patient has been dosed in ...

Onco360®, the nation’s leading independent specialty pharmacy, has been selected as a national pharmacy partner by Verastem ...

The approval marks the second international approval for rozanolixizumab (Rystiggo; UCB Pharma) for generalized myasthenia ...

However, these stocks also carry high risk, as their performance is heavily reliant on innovation, clinical trial success, ...

Ventyx Biosciences, Inc.’s VTYX share price has dipped by 5.05%, which has investors questioning if this is right time to buy ...

In a new study published in Nature, researchers at the University of Chicago Medicine Comprehensive Cancer Center explore a ...

Inhibikase Therapeutics, Inc.’s IKT share price has surged by 6.50%, which has investors questioning if this is right time to sell.

New medication appears to be safer and more effective than standard therapy, according to trial led by Chinese and US ...

The FDA approved Welireg for adult and pediatric patients 12 and older with locally advanced, unresectable or metastatic ...